Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apadenoson vs Adenosine for Myocardial Perfusion Imaging
NCT00162084Phase 3Terminated
- Sponsor
- Forest Laboratories
- Start
- Apr 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apadenoson in ischemic heart disease (IHD) (2 arms), sponsored by Forest Laboratories. Primary endpoint: Sensitivity and specificity of BMS068645 vs. adenosine. Started Apr 2005; status: terminated.
02
Drugs
apadenoson
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT00162084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162084.